Click to watch

Friends of Cancer Research (Friends) was excited to hold a webinar for advocates to explore the topics discussed during Friends 2024 Annual Meeting. On December 5, Friends hosted a “Friends Annual Meeting 2024 Recap: Sharing Next Steps and Opportunities with Advocates.” This event provided an overview of the three topics from the November 12th Friends’ Annual Meeting 2024, offering advocates the opportunity to engage directly with experts, and deepen their understanding of the topics discussed at the Annual Meeting. The meeting broke down conversations around:

• Using pragmatic trial elements to improve trial designs. Read the white paper here. 
  • Alex Wyatt, University of British Columbia, Canada. 
  • Carol Vallett, Friends Advisory Advocate 

• Approaches to ensuring interim overall survival (OS) analyses are more accurate and reliable. Read the white paper here.
  • Nevine Zariffa, NMD Group
  • Marc Theoret, OCE, U.S. FDA

• Advancing changes in circulating tumor DNA (ctDNA) as an intermediate endpoint in oncology drug development. Read the white paper here.
  • Ashita Batavia, Johnson & Johnson Innovative Medicine
  • Eva May, Friends Advisory Advocate